Want to see AGL full AI Analyst Report?
AGL Stock Chart & Stats
$96.11
-$2.27(-2.26%)
At close: 4:00 PM EDT
$96.11
-$2.27(-2.26%)
Day’s Range― - ―
52-Week Range$7.48 - $133.04
Previous CloseN/A
Volume247.62K
Average Volume (3M)321.59K
Market Cap
$1.49B
Enterprise Value$1.62K
Total Cash (Recent Filing)$185.63M
Total Debt (Recent Filing)$33.45M
Price to Earnings (P/E)―
Beta2.66
Next Earnings
Oct 29, 2026EPS Estimate
-1.18Next Dividend Ex-DateN/A
Dividend Yield0.23%
Share Statistics
EPS (TTM)-15.38
Shares Outstanding16,791,210
10 Day Avg. Volume188,290
30 Day Avg. Volume321,587
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)2.25
Price to Sales (P/S)0.05
P/FCF Ratio-2.40
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$113.22Price Target Upside17.80% Upside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)-2.08
Revenue Forecast (FY)$5.81B
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundThe swing to positive adjusted EBITDA, together with raised 2026 guidance, indicates improving operating leverage and execution. Sustaining medical-margin gains could reduce dependence on external funding and strengthen the value-based care platform.
Clinical And Data CapabilitiesImproved clinical pathways and broader payer data can help physicians identify high-risk patients earlier, reduce avoidable utilization, and improve risk adjustment. These capabilities support durable differentiation in value-based senior care.
Manageable LeverageLow leverage gives Agilon greater flexibility to manage medical-cost volatility and fund operations while it scales its platform. Although losses have weakened equity, the absence of heavy debt reduces balance-sheet amplification of operating risks.
Bears Say
Persistent Losses And Cash BurnAgilon has not yet demonstrated self-funding economics despite recent improvement. Continued negative cash flow can constrain investment in technology and market expansion, increase reliance on liquidity, and make profitability gains less durable if medical costs worsen.
Medicare Advantage Membership DeclineLower attributed membership reduces the scale of recurring capitated revenue and limits the population over which platform costs and clinical investments can be spread. Disciplined contracting may protect margins, but it creates a persistent growth headwind.
Medical-cost PressureValue-based economics remain exposed to utilization, pharmacy, and unit-cost inflation. Elevated trend assumptions and limited claims visibility can compress medical margins, while prudent reserving may create earnings volatility before contract and care-management benefits fully mature.
Agilon Health News
AGL FAQ
What was Agilon Health’s price range in the past 12 months?
Agilon Health lowest stock price was $7.48 and its highest was $133.04 in the past 12 months.
What is Agilon Health’s market cap?
Agilon Health’s market cap is $1.49B.
When is Agilon Health’s upcoming earnings report date?
Agilon Health’s upcoming earnings report date is Oct 29, 2026 which is in 52 days.
How were Agilon Health’s earnings last quarter?
Agilon Health released its earnings results on Aug 05, 2026. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $0.144 by $0.896.
Is Agilon Health overvalued?
According to Wall Street analysts Agilon Health’s price is currently Undervalued.
Does Agilon Health pay dividends?
Agilon Health pays a Quarterly dividend of $0.45 which represents an annual dividend yield of 0.23%. See more information on Agilon Health dividends here
What is Agilon Health’s EPS estimate?
Agilon Health’s EPS estimate is -1.18.
How many shares outstanding does Agilon Health have?
Agilon Health has 16,791,210 shares outstanding.
What happened to Agilon Health’s price movement after its last earnings report?
Agilon Health reported an EPS of $1.04 in its last earnings report, beating expectations of $0.144. Following the earnings report the stock price went down -19.49%.
Which hedge fund is a major shareholder of Agilon Health?
Currently, no hedge funds are holding shares in AGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agilon Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$113.22 (17.80% Upside)
$113.22 (17.80% Upside)
Blogger Sentiment
Bullish
AGL Sentiment 80%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 7.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
192.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Agilon Health
Agilon Health, Inc. provides healthcare solutions specifically designed for older adults, delivered through local primary care physicians throughout the United States. As of December 31, 2021, the company served an approximate total of 238,000 senior clients. This figure included 186,300 individuals enrolled in Medicare Advantage plans and 51,700 recipients of Medicare fee-for-service benefits. The enterprise, which commenced operations in 2016, was initially incorporated as Agilon Health Topco, Inc. before rebranding to its current name, agilon health, inc., in March 2021. Its corporate headquarters are situated in Austin, Texas.
AGL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized materially improved financial performance in Q2 (revenue growth, a large swing to positive medical margin, and a return to positive adjusted EBITDA), uplift from better-than-expected risk adjustment and stronger clinical program execution (CHF, Burden of Illness, ACO REACH). Management also highlighted enhanced data capabilities and ongoing AI/clinical pathway investments as durability drivers. Offsets and near-term risks include a year-over-year decline in MA membership driven by disciplined contracting, ongoing cost trend pressures (conservative reserving and ~7% cost trend assumptions for the back half), Part D exposure complexities, and uncertainty around 2027 contracting and membership. Overall, positives (financial turnaround, risk adjustment uplift, clinical program outcomes, and improved data visibility) outweigh the operational and timing headwinds, supporting constructive visibility into 2026 and a cautiously optimistic view into 2027.View all AGL earnings summariesAGL Stock 12 Month Forecast
Average Price Target
$113.22
▲(17.80% Upside)
Technical Analysis
Ownership Overview
5.63% Insiders
16.51% Mutual Funds
41.28% Other Institutional Investors
26.25% Public Companies and
Individual Investors